UK markets closed

BNTX Jan 2025 155.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
11.630.00 (0.00%)
As of 11:54AM EDT. Market open.
Full screen
Previous close11.63
Expiry date2025-01-17
Day's range11.63 - 11.63
Contract rangeN/A
Open interest15
  • Motley Fool

    Why Pfizer and BioNTech Stocks Zoomed Higher Today

    The fight against COVID-19 isn't over yet, and the two companies remain very much in the battle.

  • Motley Fool

    Why CureVac Stock Plunged Today

    Shares of CureVac (NASDAQ: CVAC) were down 9.1% as of 2:45 p.m. ET Thursday after a German court temporarily suspended the biopharmaceutical company's patent trial against BioNTech (NASDAQ: BNTX). CureVac previously failed to develop a successful COVID-19 vaccine during the pandemic, opting instead to focus on potential second-generation vaccines in partnership with GlaxoSmithKline. BioNTech, by contrast, generated tens of billions of dollars in annual revenue from its successful mRNA vaccines developed in partnership with Pfizer.

  • Globe Newswire

    Pfizer and BioNTech Receive Health Canada Authorization for XBB.1.5-Adapted Monovalent COVID-19 Vaccine

    COMIRNATY Omicron XBB.1.5-adapted monovalent COVID-19 vaccine is now authorized in Canada for individuals 6 months of age and olderNew Omicron XBB.1.5-adapted COVID-19 vaccine is administered as a single dose for individuals 5 years of age and older, regardless of COVID-19 vaccination history. In children 6 months through 4 years of age the vaccine is administered as a three-dose series in those without a history of completion of a COVID-19 primary vaccination course, or as a single dose in thos